For how we live.
A retrospective analysis of 54,114 women on a digital weight-loss service found those with PCOS lost as much as those without. But only 40 PCOS users reached the 10-month mark, and the data are observational.
The 2023 global guideline puts lifestyle first for everyone, letrozole first for fertility, and the pill for cycles and excess hair — while rating much of its own evidence low to moderate quality.
Using genetic variants as instruments, researchers found exercise and wellbeing lowered risk of PCOS, endometriosis and menstrual disorders, while screen time and mood swings raised it.
An 876-participant double-blind trial across 24 Chinese fertility centres nearly doubled serum 25-OHD in women with PCOS. Live births were 52.0% against 50.2% on placebo.
A double-blind trial randomised 750 women with polycystic ovary syndrome to one drug or the other. Letrozole produced more live births and more ovulation — and is now the guideline's first choice for fertility.